935 results about "Carcinoma Cell" patented technology

Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.

Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of:(a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and / or TRAIL-R2;(b) not having effect on normal human cells expressing TRAIL-R1 and / or TRAIL-R2; and(c) not inducing human hepatocyte toxicity.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

A method for evaluating hepatocellular carcinoma in a subject is provided. In certain embodiments, the method comprises: a) obtaining a hepatocellular carcinoma protein marker profile for a sample obtained from the subject; and b) comparing the protein marker profile to a control profile.

Objective methods for detecting, diagnosing, treating and preventing hepatocellular carcinoma (HCC) are described herein. In particular, the present invention relates to two genes up-regulated in HCC cells as compared to normal cells, referred to herein as MGC47816 and HES6. In one embodiment, the diagnostic method involves the determining the expression level of MGC47816 or HES6 that discriminate between hepatocellular carcinoma cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of HCC, methods of treating HCC, and methods for vaccinating a subject against HCC.

The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.

Methods for treating a human having heptocellular carcinoma comprising administering to the human a therapeutically effective amount of Compound A:or a pharmaceutically acceptable salt thereof, wherein the human has a complete response or partial response.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

The invention discloses erlotinib modified 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene derivatives, and a preparation method and application thereof. According to the invention, erlotinib which is a listed small-molecule inhibitor is used as a tumor target and is covalently connected to a 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene photosensitizer capable of being used for photodynamic therapy by the click reaction so as to obtain third-generation anti-tumor photosensitizers capable of being used for targeted therapy, namely, a double-erlotinib modified 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene derivative and a single-erlotinib modified 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene derivative. Meanwhile, by using the erlotinib modified 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene derivatives as research objects and respectively using human body hepatoma carcinoma cells HepG2 and HELF (Human Embryonic Lung Fibroblast) as tested cell strains, research on in vitro anti-tumor activity of the erlotinib modified 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene derivatives is developed, a prodrug suitable for molecular targeted therapy is screened out and the foundation is laid for application of the erlotinib modified 4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene derivatives to targeted therapy of cancers. A synthetic method of the derivatives is simple; raw materials of the derivatives are easy to obtain and low in cost, have few side effects and high yield, are easy to purify and are beneficial to industrial production.